Indian-Origin Scientist In UK Gets World's First Far-Side Moon Dust From China
A UK-based Indian-origin scientist has received a portion of the world's first lunar soil samples collected from the Moon's far side, courtesy of China's Chang'e-6 mission, according to BBC. This historic achievement marks the first time any nation has retrieved material from the Moon's far side, a region previously unexplored due to communication challenges.
According to BBC, Professor Mahesh Anand is the only scientist in the UK to have been loaned this extremely rare material, which he describes as "more precious than gold dust".
"Nobody in the world had access to China's samples, so this is a great honour and a huge privilege," he says.
After grinding and zapping the dust with lasers, Professor Anand's team hopes to answer fundamental questions about how the Moon formed and about the early years of planet Earth.
Inside the grains of dust could be evidence to back up scientists' theory that the Moon was made from the debris thrown out when Earth struck a Mars-sized planet 4.5 billion years ago.
China collected the rocks on its Chang'e 5 space mission in 2020 when it landed on a volcanic area called Mons Rumker.
A robotic arm drilled into the soil to collect 2kg of material, which was brought back to Earth in a capsule which landed in Inner Mongolia, as per BBC report.
The Chang'e-6 mission successfully returned approximately 1.9 kilograms of lunar material in June 2024. These samples are being distributed to international researchers for analysis. Notably, the lunar soil exhibits distinct characteristics compared to previous samples, including a more porous structure and differing mineral compositions, such as higher plagioclase and lower olivine content.
This collaboration underscores China's commitment to international scientific cooperation in space exploration. The involvement of an Indian-origin scientist in the UK highlights the global nature of lunar research and the shared pursuit of understanding our celestial neighbour.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Dr Reddy's, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Dr Reddy's Laboratories has entered into a collaboration with Reykjavik, Ireland-based biotech company Alvotech to co-develop, manufacture and commercialise a biosimilar version of blockbuster cancer drug Keytruda for the global (generic name is pembrolizumab ), manufactured and marketed by Merck & Co , is the most successful medicine, recording worldwide sales of $29.5 billion in 2024. It is used to treat multiple forms of the terms of the agreement, both companies will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, Hyderabad-based DRL said in a statement on to certain exceptions, each party will have the right to commercialise the product traditional generics, which often face automatic patent infringement claims, biosimilars are developed more like original drugs, complete with clinical trials and patent disclosures, giving them a better chance of overcoming legal challenges. Also, Merck's core patents on pembrolizumab in the US are expected to start expiring around 2028.'This (collaboration) demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide,' Erez Israeli, chief executive of DRL, said.Róbert Wessman, chairman and CEO of Alvotech, said, 'The agreement enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide.'Keytruda is approved in the US to treat 40 cancers, unlike most medicines that treat a few indications or medical India, it is approved for use in 17 indications across 10 cancers or tumour types. Oncologists mostly prescribe it to treat certain types of lung cancers, followed by gastrointestinal cancer, triple-negative breast cancer and head and neck helps the body's immune system, which is the T-cells, to detect and fight cancer cells that hide and spread in organs.'Oncology has been a top focus therapy area for us, and this collaboration will enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology ,' Israeli has been out of reach for most patients in India due to its exorbitant cost – roughly about Rs 2 lakhs for each dose. However, with Merck's patent set to expire in a few years and with Indian drug manufacturers looking to come up with more affordable versions of the drug it may play a crucial role in widening adoption across a larger cohort of patients.
India.com
an hour ago
- India.com
India's Rs 548 crore Space Leap: Shukla rides the Falcon 9 to the ISS
On June 10, 2025, at 5:52 PM IST (8:22 AM EDT), Group Captain Shubhanshu Shukla will lift off to the International Space Station (ISS), becoming the first Indian astronaut since 1984 to undertake such a journey. As the pilot of Axiom Mission 4 (Ax-4), he will fly aboard a SpaceX Crew Dragon spacecraft, launched on a Falcon 9 rocket from NASA's Kennedy Space Center in Florida. After approximately 28 hours of travel, the crew is expected to dock with the ISS by 10:00 PM IST on June 11, 2025. Shukla joins an elite international crew: Commander Peggy Whitson (USA, Axiom Space), and Mission Specialists Sławosz Uznański-Wiśniewski (Poland, ESA) and Tibor Kapu (Hungary, Hunor Programme). The team will spend up to 14 days aboard the ISS, conducting over 60 scientific experiments from 31 countries, including seven from India, such as research on plant growth in microgravity, muscle regeneration, and tardigrade resilience. Born on October 10, 1985, in Lucknow, Shukla is a decorated Indian Air Force test pilot with over 2,000 flight hours. He has undergone rigorous astronaut training in Russia and at SpaceX facilities in the US, and will assist in spacecraft navigation, docking, and emergency procedures during the mission. But beyond his technical role, Shukla carries India's cultural pride into space—bringing along items designed by National Institute of Design (NID) students, performing yoga in microgravity, sharing Indian delicacies like mango nectar and moong dal halwa, and planning live interactions with Indian school children and possibly Prime Minister Narendra Modi. SpaceX has revolutionized space travel economics. While NASA pays around $55 million per seat under its commercial crew program, private clients like Axiom Space are charged $52–55 million per seat, excluding stay-related fees. NASA charges $35,000 per night per astronaut for use of the ISS. India's investment for Shukla's mission seat is around ₹548 crore (approximately $65 million), while the total private mission cost per astronaut can go up to $100 million, including training and logistics. In comparison, Russia's Soyuz costs around $80–86 million per seat, Boeing's Starliner costs about $90 million, and the now-retired Space Shuttle had a cost of approximately $170 million per astronaut. For reference, cargo missions on SpaceX's Dragon cost anywhere between $21,000 and $89,000 per kg, while human missions are far costlier due to added life support and safety systems. Shukla's mission is more than just a spaceflight—it's a symbol of India's return to human space exploration. He carries a special swan named 'Joy', representing wisdom (India), resilience (Poland), and grace (Hungary). The scientific experiments onboard are expected to contribute to India's ambition of establishing a space station by 2035 and support its moon mission goals set for 2047. This mission also strengthens international space ties, especially between India and the US, following commitments made during PM Modi's 2023 visit. In every sense, Group Captain Shubhanshu Shukla's journey aboard the human-rated Falcon 9 rocket is a giant leap for India—both in science and symbolism. With his successful flight, India not only rekindles its human spaceflight legacy after four decades but also sets the stage for greater roles in global space partnerships, cutting-edge research, and inspiration for the next generation of Indian scientists, engineers, and dreamers. —E.O.M (Girish Linganna is an award-winning science communicator and a Defence, Aerospace & Geopolitical is the Managing Director of ADD Engineering Components India Pvt. Ltd., a subsidiary of ADD Engineering GmbH, Germany )
Time of India
3 hours ago
- Time of India
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda HYDERABAD: Dr Reddy's Laboratories has entered into a collaboration and license agreement with Iceland-based biotech player Alvotech for the co-development, manufacturing and commercialiation of a biosimilar of Merck Sharp & Dohme's blockbuster drug Keytruda (pembrolizumab). Keytruda, which is used for the treatment of various types of cancer, clocked sales of over US$29.5 billion in 2024. The collaboration will combine Dr Reddy's and Alvotech's capabilities in biosimilars to speed up the development process and extend the global reach of the biosimilar candidate. As per the agreement, the two companies will share the costs and responsibilities for jointly developing and manufacturing the biosimilar candidate and subject to certain exceptions, each company will have the right to commercialise the product globally, Dr Reddy's said on Thursday. 'The agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patients worldwide,' said Róbert Wessman, chairman & CEO, Alvotech. Dr Reddy's CEO, Erez Israeli, said the pact demonstrates the company's ability to develop and manufacture high-quality and affordable treatment options for patients worldwide. 'Oncology has been a top focus therapy area for us, and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Israeli added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
